Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 714

The DOI matches its Crossref record.

Clinical Uses of α2-Adrenergic Agonists

Kamibayashi, Takahiko, Maze, Mervyn, Weiskopf, Richard B., Weiskopf, Richard B, Todd, Michael M · 2000 · Anesthesiology

Abstract

SINCE the early 1970s, α2-adrenergic receptor agonists have been used successfully to treat patients with hypertension and patients withdrawing from long-term abuse of drugs or alcohol. α2Agonists produce diverse responses, including analgesia, anxiolysis, sedation, and sympatholysis, each of which has been reported in the treatment of surgical and chronic pain patients. Recently, the Food and Drug Administration registered two novel α2-adrenergic agonists. A role has been found for epidural clonidine (Duraclon, Fujisawa USA, Melrose Park, IL) in the management of pain in a variety of clinical settings. Because this has been discussed extensively in a recent review, 1studies up to that time will not be discussed exhaustively herein. Dexmedetomidine (Precedex, Abbott Laboratories Inc., Abbott Park, IL) has been registered for use as a sedative–analgesic in the intensive care setting. In addition to this approved setting, α2agonists also have been studied in several other perioperative settings, which will be discussed. Allusion to these “off-label” uses does not necessarily indicate that these applications are advocated by the authors. The pharmacologic basis and the clinical application of α2-adrenergic agonists will be discussed.α2-Adrenergic agonists produce clinical effects after binding to α2-adrenergic receptors, of which there are three subtypes (α2A, α2B, and α2C). These receptor subtypes are distributed ubiquitously, and each may be uniquely responsible for some, but not all, of the actions of α2agonists; for example, the α2B-adrenoceptor subtype mediates the short-term hypertensive response to α2agonists, 2whereas the α2Aadrenoceptor is responsible for the anesthetic and sympatholytic responses. 3All the subtypes produce cellular action by signaling through a G-protein; a functional assay of G-protein activation has been implemented to screen for subtype specificity and effectiveness of the various α2agonists. From these and other related studies, it is apparent that there are no subtype-selective agonists; therefore, the goal of producing a single discrete desirable α2action (e.g. , analgesia) without producing another unwanted effect (e.g. , hypotension) is elusive. G-proteins couple to effector mechanisms, which appear to differ depending on the receptor subtype (and possibly the location of the receptor). For example, the α2A-adrenoceptor subtype seems to couple in an inhibitory fashion to the L-type calcium channel in the locus ceruleus, whereas, in the vasculature, the α2B-adrenoceptor subtype couples in an excitatory manner to the same effector mechanism.Because all of the clinically available α2agonists have an imidazole ring in their structure, these compounds interact with the imidazoline receptor. It is unlikely that these receptors transduce the cardiovascular responses to α2agonists because studies of genetically engineered mice have indicated that each of the cardiovascular properties of the α2agonists seem to be mediated by α2adrenoceptors (with the possible exception of enhanced vagal tone).α2Agonists can produce either hypotension or hypertension. At lower doses, the dominant action of α2agonists is sympatholysis, i.e. , the ability to block the sympathetic arm of the autonomic nervous system, which is mediated by the α2A-adrenergic receptor subtype. 3There are several well-documented mechanisms for this activity, including inhibition of firing of the locus ceruleus (the pivotal noradrenergic relay nucleus in the brain stem) and inhibition of norepinephrine release at the neuroeffector junction. Bosnjak et al. 4have suggested that the central and peripheral sympatholytic effects of α2-adrenoceptor stimulation may be augmented further by inhibition of ganglionic transmission (fig. 1).At higher doses of α2agonists, the hypertensive action dominates via the activation of α2Badrenoceptors, located on smooth muscle cells in the resistance vessels. There is even some suggestion that this receptor subtype may be involved in the pathogenesis of essential hypertension. 5Pretreatment with a peripherally restricted antagonist before intravenous administration of α2agonists may become a useful pharmacologic strategy to facilitate the advantageous sedative–hypnotic and central sympatholytic actions while avoiding the possible detrimental hemodynamic effects of vasoconstriction, which are mediated in the periphery. Thus far, no peripherally restricted antagonist is clinically available.In addition to the well-documented hypnotic–sedative, analgesic, and anxiolytic actions of α2agonists, spatial working memory also may be modulated via the α2A-adrenoceptor subtype. 6If confirmed in humans, this would represent the first sedative–hypnotic class of agent that enhances, rather than diminishes, cognitive performance. Using experimental strategies that either “knocked out” or overexpressed the gene that encodes α2Cadrenoceptors, Scheinin et al. 7have shed light on the mechanism for the anxiolytic acti

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00000542-200011000-00030

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 714

Metadata

Authors
Kamibayashi, T., Maze, M., Weiskopf, R. B., Weiskopf, R. B., & Todd, M. M.
Venue
Anesthesiology
Published
2000-11-01
Volume
93
Issue
5
Pages
1345-1349
ISSN
0003-3022 (ISSN-L)
OpenAlex
W2034557139
Cited by
714
References
0
FWCI
9.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Uses of α2-Adrenergic Agonists. https://app.cochat.ai/papers/10.1097/00000542-200011000-00030
The paper
Kamibayashi, T., Maze, M., Weiskopf, R. B., Weiskopf, R. B., & Todd, M. M. (2000). Clinical Uses of α2-Adrenergic Agonists. Anesthesiology. https://doi.org/10.1097/00000542-200011000-00030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.